Jazz Pharmaceuticals PLC said on Thursday its sleep disorder drug Xywav received regulatory approval for the expanded use in patients suffering from excessive daytime sleepiness despite a good night’s sleep. Xywav is currently approved in the United States for the treatment of excessive daytime sleepiness and sudden loss of muscle tone in patients aged seven…